Episodic Future Thinking to Improve Management of Type 2 Diabetes: Remote Delivery and Outcomes Assessment
Primary Purpose
Type 2 Diabetes, Overweight and Obesity
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Episodic Future Thinking
Healthy Information Thinking
Sponsored by
About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- HbA1c greater than or equal to 7.7%
- from urban or rural area
- body mass index greater than or equal to 30
Exclusion Criteria:
- gestational diabetes
- pregnancy or lactating
- not ambulatory
- intellectual impairment
- unmanaged comorbid psychiatric diagnosis (including eating disorders)
Sites / Locations
- Fralin Biomedical Research Institute at VTCRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Episodic Future Thinking
Healthy Information Thinking
Arm Description
Participants will generate vivid, episodic events and be prompted via a guided smartphone app to engage in EFT in their daily lives. EFT will be paired with diet and physical activity support.
Participants will be prompted via a guided smartphone app to thinking about their written responses to informational health vignettes during their daily lives. The HIT condition will be paired with diet and physical activity support.
Outcomes
Primary Outcome Measures
Change in glycemic control from baseline (Week 0) to Week 8
Hemoglobin A1c (HbA1C) will be assessed by the A1CNOW system
Change in glycemic control from baseline (Week 0) to Week 24
Hemoglobin A1c (HbA1C) will be assessed by the A1CNOW system
Change in body mass index from baseline (Week 0) to Week 8
Weight will be assessed with a wireless-enabled scale. Height will be assessed through self-report. Height and weight will be used to calculate BMI (kg/m2).
Change in body mass index from baseline (Week 0) to Week 24
Weight will be assessed with a wireless-enabled scale. Height will be assessed through self-report. Height and weight will be used to calculate BMI (kg/m2).
Secondary Outcome Measures
Change in dietary intake from baseline (Week 0) to Week 8
Dietary intake will be assessed by ASA-24 online food recalls
Change in dietary intake from baseline (Week 0) to Week 24
Dietary intake will be assessed by ASA-24 online food recalls
Change in physical activity from baseline (Week 0) to Week 8
Physical activity will be assessed using the International Physical Activity Questionnaire Short Form (IPAQ-SF)
Change in physical activity from baseline (Week 0) to Week 24
Physical activity will be assessed using the International Physical Activity Questionnaire Short Form (IPAQ-SF)
Change in self-reported adherence to glucose-lowering medication from baseline (Week 0) to Week 8
Medication adherence will self reported by an 11-point assessment. Participants will self-report the frequency they have taken all of their glucose-lowering medications
Change in self-reported adherence to glucose-lowering medication from baseline (Week 0) to Week 24
Medication adherence will self reported by an 11-point assessment. Participants will self-report the frequency they have taken all of their glucose-lowering medications
Ease of Use and Treatment Effectiveness Questionnaire, Likert scale
Perceived ease of use and effectiveness of assessment methods and intervention components will be collected by self-reported ratings on 5-point Likert-style scales.
Full Information
NCT ID
NCT05280925
First Posted
February 15, 2022
Last Updated
November 21, 2022
Sponsor
Virginia Polytechnic Institute and State University
Collaborators
Carilion Clinic, University at Buffalo
1. Study Identification
Unique Protocol Identification Number
NCT05280925
Brief Title
Episodic Future Thinking to Improve Management of Type 2 Diabetes: Remote Delivery and Outcomes Assessment
Official Title
Episodic Future Thinking to Improve Management of Type 2 Diabetes in Rural and Urban Patients: Remote Delivery and Outcomes Assessment to Increase Reach and Dissemination
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 20, 2022 (Actual)
Primary Completion Date
November 1, 2024 (Anticipated)
Study Completion Date
November 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Virginia Polytechnic Institute and State University
Collaborators
Carilion Clinic, University at Buffalo
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Successful management of type 2 diabetes (T2D) requires adherence to a dietary, physical activity, and medication plan agreed upon between a patient and their healthcare providers. The lifestyle changes involved in these collaborative care plans (CCPs) often provide little to no short-term benefit and may instead be aversive (e.g., caloric restriction and physical activity). However, these changes provide critical health benefits in the future, allowing patients with T2D to halt or reverse disease progression and avoid T2D-related complications (e.g., renal disease or diabetic retinopathy). Thus, successful management of T2D requires one's present behavior to be guided by future outcomes. Unfortunately, accumulating evidence indicates that individuals with T2D and prediabetes show elevated rates of delay discounting (i.e., devaluation of delayed consequences). Moreover, high rates of delay discounting are cross-sectionally and longitudinally associated with poor treatment adherence and clinical outcomes in T2D and prediabetes. These data suggest that high rates of delay discounting prevent successful management of T2D through a mechanism in which the health benefits of lifestyle changes are too delayed to motivate behavioral change. Thus, we believe delay discounting serves as a therapeutic target in T2D, where improving participants' valuation of the future will facilitate healthy lifestyle changes and, in turn, improve T2D management. This study will conduct a randomized 24-week remote clinical trial comparing repeated measures ANOVA, with group (episodic future thinking [EFT]/control) and area (urban vs. rural) as between-subjects factors, and time (baseline, week 8, and week 24 assessments) as within-subjects factors in adults with type 2 diabetes.
Detailed Description
In a 24-week trial, 120 participants from both urban (n = 60) and rural (n = 60) areas will be assigned receive either remotely delivered episodic future thinking or a control condition. Participants will be prompted three times daily to engage in episodic future thinking or control thinking. All participants will also receive virtual diet and physical activity support; self-monitoring of diet, activity, and weight; and case management. Outcome measures will be assessed at baseline, 8 weeks, and 24 weeks.
In the week following informed consent, participants will complete remote assessments of dietary intake (ASA-24 food recalls) and self-reported physical activity (IPAQ-SF), as well as self-administered survey (requiring approximately 10 minutes) to obtain sociodemographic information and delay discounting measures.
The week following baseline, all participants will begin phone-based case management; online self-monitoring of diet, activity, and weight; and diet and activity support. Beginning in Week 3, participants will begin episodic future thinking or control thinking conditions. Here, participants assigned to the EFT group will complete an episodic event generation task to generate a number of positive, vivid events that may occur at several time frames in the future (1 month, 3 months, 6 months, 1 year, 3 years, 5 years, and 10 years; a total of 7 events). During this task, participants will also generate corresponding short text descriptions that will be used as cues to prompt episodic thinking in the natural environment. Participants will regenerate all cues during weeks 8, 16, and 24, with partial regenerations (regenerating only the 1 month and 3 month cues) scheduled during weeks 12 and 20. Participants will complete delay discounting tasks while viewing and imagining their EFT or HIT cues in weeks 3 and 16.
On the day following the event/cue generation, participants will begin thrice-daily smartphone app prompts to engage in EFT. In each prompt, participants will be presented with one of their EFT cues, chosen randomly, and asked to read and vividly imagine this event for a period of 30-60 seconds in a quiet location.
In contrast to the EFT condition, the control condition will be healthy information thinking (HIT). Specifically, participants assigned to the HIT group will be asked to read informational health vignettes on various topics related to T2D and health, adapted from publicly available information (e.g., information on the role of insulin and insulin resistance in T2D, nutrition labeling, understanding T2D risk factors). Participants will then be asked to describe, in 1-2 sentences, a specific piece of information they learned about each topic. This process is designed to mimic the event generation task used for the EFT group, with the number of topics matched to the number of future EFT events. Beginning in Week 3, participants will receive smartphone prompts to read and consider their self-generated topic descriptions with the same frequency and at approximately the same times of day as the EFT group. Moreover, HIT participants will regenerate these descriptions with the same frequency as the EFT group.
At Weeks 8 and 24, participants will complete the same primary and secondary outcome measures they completed during the baseline week, including delay discounting, BMI, and HbA1c.
In addition, during a debriefing stage after Week 24, participants will also rate the perceived helpfulness and convenience of each intervention component (EFT/control prompting, diet and activity support, self-monitoring, and case management) and remote outcomes assessment methods.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Overweight and Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
24-week remote randomized controlled trial. Analysis plan: repeated measures ANOVA, with group (EFT/control) and area (urban vs. rural) as between-subjects factors, and time (baseline, week 8, and week 24 assessments) as within-subjects factors
Masking
ParticipantOutcomes Assessor
Masking Description
Participants assigned to both groups will be masked to experimental hypotheses. Research personnel who will be conducting assessment sessions, including weight and HbA1c measurements, will not be informed of participants' group assignments
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Episodic Future Thinking
Arm Type
Experimental
Arm Description
Participants will generate vivid, episodic events and be prompted via a guided smartphone app to engage in EFT in their daily lives. EFT will be paired with diet and physical activity support.
Arm Title
Healthy Information Thinking
Arm Type
Active Comparator
Arm Description
Participants will be prompted via a guided smartphone app to thinking about their written responses to informational health vignettes during their daily lives. The HIT condition will be paired with diet and physical activity support.
Intervention Type
Behavioral
Intervention Name(s)
Episodic Future Thinking
Intervention Description
Participants will be prompted three times daily to think vividly about personally meaningful future events.
Intervention Type
Behavioral
Intervention Name(s)
Healthy Information Thinking
Intervention Description
Participants will be prompted three times daily to think about their responses to informational health vignettes.
Primary Outcome Measure Information:
Title
Change in glycemic control from baseline (Week 0) to Week 8
Description
Hemoglobin A1c (HbA1C) will be assessed by the A1CNOW system
Time Frame
Baseline, Week 8
Title
Change in glycemic control from baseline (Week 0) to Week 24
Description
Hemoglobin A1c (HbA1C) will be assessed by the A1CNOW system
Time Frame
Baseline, Week 24
Title
Change in body mass index from baseline (Week 0) to Week 8
Description
Weight will be assessed with a wireless-enabled scale. Height will be assessed through self-report. Height and weight will be used to calculate BMI (kg/m2).
Time Frame
Baseline, Week 8
Title
Change in body mass index from baseline (Week 0) to Week 24
Description
Weight will be assessed with a wireless-enabled scale. Height will be assessed through self-report. Height and weight will be used to calculate BMI (kg/m2).
Time Frame
Baseline, Week 24
Secondary Outcome Measure Information:
Title
Change in dietary intake from baseline (Week 0) to Week 8
Description
Dietary intake will be assessed by ASA-24 online food recalls
Time Frame
Baseline, Week 8
Title
Change in dietary intake from baseline (Week 0) to Week 24
Description
Dietary intake will be assessed by ASA-24 online food recalls
Time Frame
Baseline, Week 24
Title
Change in physical activity from baseline (Week 0) to Week 8
Description
Physical activity will be assessed using the International Physical Activity Questionnaire Short Form (IPAQ-SF)
Time Frame
Baseline, Week 8
Title
Change in physical activity from baseline (Week 0) to Week 24
Description
Physical activity will be assessed using the International Physical Activity Questionnaire Short Form (IPAQ-SF)
Time Frame
Baseline, Week 24
Title
Change in self-reported adherence to glucose-lowering medication from baseline (Week 0) to Week 8
Description
Medication adherence will self reported by an 11-point assessment. Participants will self-report the frequency they have taken all of their glucose-lowering medications
Time Frame
Baseline, Week 8
Title
Change in self-reported adherence to glucose-lowering medication from baseline (Week 0) to Week 24
Description
Medication adherence will self reported by an 11-point assessment. Participants will self-report the frequency they have taken all of their glucose-lowering medications
Time Frame
Baseline, Week 24
Title
Ease of Use and Treatment Effectiveness Questionnaire, Likert scale
Description
Perceived ease of use and effectiveness of assessment methods and intervention components will be collected by self-reported ratings on 5-point Likert-style scales.
Time Frame
Week 24
Other Pre-specified Outcome Measures:
Title
Change in delay discounting from baseline (Week 0) to Week 8
Description
Monetary delay discounting will be assessed by an adjusting-amount task
Time Frame
Baseline, Week 8
Title
Change in delay discounting from baseline (Week 0) to Week 24
Description
Monetary delay discounting will be assessed by an adjusting-amount task
Time Frame
Baseline, Week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
HbA1c greater than or equal to 7.7%
from urban or rural area
body mass index greater than or equal to 30
Exclusion Criteria:
gestational diabetes
pregnancy or lactating
not ambulatory
intellectual impairment
unmanaged comorbid psychiatric diagnosis (including eating disorders)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jeffrey Stein, PhD
Phone
540-526-2124
Email
jstein1@vtc.vt.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Megan Stuart
Email
stuartma@vtc.vt.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Stein, PhD
Organizational Affiliation
Fralin Biomedical Research Institute at Virginia Tech Carilion
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fralin Biomedical Research Institute at VTC
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeffrey Stein, PhD
Email
jstein1@vtc.vt.edu
First Name & Middle Initial & Last Name & Degree
Kirstin Gatchalian, BS
Email
kmgatch@vtc.vt.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Episodic Future Thinking to Improve Management of Type 2 Diabetes: Remote Delivery and Outcomes Assessment
We'll reach out to this number within 24 hrs